clinical trial · NCT07187531
SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes
SAb Biotherapeutics, Inc.·phase2·recruiting·n = 159
Type 1 DiabetesHigh Dose SAB-142Low Dose SAB-142Placebo
brief summary
This is a Phase 2b, investigator- and participant-blinded, placebo-controlled, parallel-arm study to evaluate the efficacy, safety and tolerability of SAB 142 in patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D).
started
Nov 25, 2025
primary completion
Nov 1, 2027
completion
Dec 1, 2028
last updated
May 12, 2026
official title
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients With Stage 3 New Onset of Type 1 Diabetes (NOT1D)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol